This is the gateway to restoring the body’s inherent biological instruction set.
Arcane was born to eliminate human suffering by restoring the body’s inherent biological instruction set.
We’ve dismantled traditional pharma paradigms, enabling treatments to go from lab to market at unprecedented speed.
Imagine a world that goes beyond treating disease and instead restores and resets the human genome entirely. Our breakthroughs in Elastin-Like Polypeptides (ELPs) — customizable protein carriers — provided the game-changing technology to turn cutting-edge biologics into easy-to-use topical, intranasal, and oral therapies for neurological & chronic disease.
Founded through a strategic partnership between Arcane and ExtraCellular Concepts, our journey began at the intersection of visionary biotech innovation and agile entrepreneurial execution. Arcane’s role is to turn these revolutionary breakthroughs in ELP’s into flexible, user-friendly treatments and deliver them to humankind.
Disrupting humanity through restoration, not evolution.
Elastin-Like Polypeptides: One modular platform with infinite therapeutic potential.
Our core breakthrough lies in a programmable therapeutic platform based on human elastin-like polypeptides (ELPs). These synthetic proteins act as intelligent delivery vehicles capable of targeting specific tissues, responding to biological cues, and triggering regenerative cascades across a broad spectrum of disease states. ELP constructs allow for the attachment of gene sequences, exosomes, or protein payloads—opening a path to both direct-to-consumer therapeutics and high-value pharmaceutical applications.
ELPs mimic the behavior of natural elastin, a flexible and abundant protein in human connective tissue, allowing them to navigate the body’s internal environment with minimal disruption. They can be engineered to respond to specific biological cues—such as temperature, pH, or enzymes—triggering the controlled release of therapeutic agents directly at the site of dysfunction. What makes this transformative is not just the targeted delivery—it’s the ability of ELPs to restore the body’s own biological instructions. Rather than forcing change through brute pharmaceutical force, ELPs act more like cellular reset buttons, realigning dysfunctional tissue behavior and reactivating innate healing pathways.
This enables regeneration at a foundational level, promoting repair across skin, nerve, muscle, and metabolic systems.Crucially, this is achieved without the need for injections, viral vectors, or complex cold-chain logistics. ELPs are non-immunogenic, biodegradable, and scalable, opening the door to a new class of accessible, non-invasive biologic therapies. This foundational platform positions Arcane to address a vast range of chronic and degenerative conditions—not by treating symptoms, but by reprogramming cellular behavior itself.
Arcane was born to eliminate human suffering by restoring the body’s inherent biological instruction set.
Our breakthroughs in Elastin-Like Polypeptides (ELPs) — customizable protein carriers — provided the game-changing technology to turn cutting-edge biologics into easy-to-use topical, intranasal, and oral therapies for neurological & chronic disease. We’ve dismantled traditional pharma paradigms, enabling treatments to go from lab to market at unprecedented speed. Imagine a world that goes beyond treating disease and instead restores and resets the human genome entirely.
Founded through a strategic partnership between Arcane and ExtraCellular Concepts, our journey began at the intersection of visionary biotech innovation and agile entrepreneurial execution. Arcane’s role is to turn these revolutionary breakthroughs in ELP’s into flexible, user-friendly treatments and deliver them to humankind.
Disrupting humanity through restoration, not evolution.
Arcane has developed a programmable therapeutic platform based on human elastin-like polypeptides (ELPs). These synthetic proteins act as intelligent delivery vehicles capable of targeting specific tissues, responding to biological cues, and triggering regenerative cascades across a broad spectrum of disease states.
Our ELP constructs allow for the attachment of gene sequences, exosomes, or protein payloads—opening a path to both direct-to-consumer therapeutics and high-value pharmaceutical applications.
Arcane was born to eliminate human suffering by restoring the body’s inherent biological instruction set.
Our breakthroughs in Elastin-Like Polypeptides (ELPs) — customizable protein carriers — provided the game-changing technology to turn cutting-edge biologics into easy-to-use topical, intranasal, and oral therapies for neurological & chronic disease. We’ve dismantled traditional pharma paradigms, enabling treatments to go from lab to market at unprecedented speed. Imagine a world that goes beyond treating disease and instead restores and resets the human genome entirely.
Founded through a strategic partnership between Arcane and ExtraCellular Concepts, our journey began at the intersection of visionary biotech innovation and agile entrepreneurial execution. Arcane’s role is to turn these revolutionary breakthroughs in ELP’s into flexible, user-friendly treatments and deliver them to humankind.
a
Enabling regeneration at a foundational level, promoting repair across skin, nerve, muscle, and metabolic systems.
Enabling regeneration at a foundational level, promoting repair across skin, nerve, muscle, and metabolic systems.
Enabling regeneration at a foundational level, promoting repair across skin, nerve, muscle, and metabolic systems.
One modular platform.
Infinite therapeutic potential.
Not by treating symptoms, but by reprogramming cellular behavior itself.
Arcane’s core breakthrough centers on Elastin-Like Polypeptides (ELPs)—programmable biopolymers that act like microscopic delivery drones, but with biologically native precision. These synthetic proteins mimic the behavior of natural elastin, a flexible and abundant protein in human connective tissue, allowing them to navigate the body’s internal environment with minimal disruption. ELPs can be engineered to respond to specific biological cues—such as temperature, pH, or enzymes—triggering the controlled release of therapeutic agents directly at the site of dysfunction. What makes this transformative is not just the targeted delivery—it’s the ability of ELPs to restore the body’s own biological instructions.
Rather than forcing change through brute pharmaceutical force, ELPs act more like cellular reset buttons, realigning dysfunctional tissue behavior and reactivating innate healing pathways. This enables regeneration at a foundational level, promoting repair across skin, nerve, muscle, and metabolic systems.
Crucially, this is achieved without the need for injections, viral vectors, or complex cold-chain logistics. ELPs are non-immunogenic, biodegradable, and scalable, opening the door to a new class of accessible, non-invasive biologic therapies. This foundational platform positions Arcane to address a vast range of chronic and degenerative conditions—not by treating symptoms, but by reprogramming cellular behavior itself.
One modular platform. Infinite therapeutic potential.
reprograms the body’s original biology—restoring function at the source and eliminating the conditions that require intervention in the first place.
Arcane’s core breakthrough centers on Elastin-Like Polypeptides (ELPs)—programmable biopolymers that act like microscopic delivery drones, but with biologically native precision. These synthetic proteins mimic the behavior of natural elastin, a flexible and abundant protein in human connective tissue, allowing them to navigate the body’s internal environment with minimal disruption. ELPs can be engineered to respond to specific biological cues—such as temperature, pH, or enzymes—triggering the controlled release of therapeutic agents directly at the site of dysfunction. Crucially, this is achieved without the need for injections, viral vectors, or complex cold-chain logistics. ELPs are non-immunogenic, biodegradable, and scalable, opening the door to a new class of accessible, non-invasive biologic therapies.
This foundational platform positions Arcane to address a vast range of chronic and degenerative conditions—not by treating symptoms, but by reprogramming cellular behavior itself. What makes this transformative is not just the targeted delivery—it’s the ability of ELPs to restore the body’s own biological instructions. Rather than forcing change through brute pharmaceutical force, ELPs act more like cellular reset buttons, realigning dysfunctional tissue behavior and reactivating innate healing pathways. This enables regeneration at a foundational level, promoting repair across skin, nerve, muscle, and metabolic systems.
Disrupting humanity through restoration, not evolution.
Arcane has developed a programmable therapeutic platform based on human elastin-like polypeptides (ELPs). These synthetic proteins act as intelligent delivery vehicles capable of targeting specific tissues, responding to biological cues, and triggering regenerative cascades across a broad spectrum of disease states. Our ELP constructs allow for the attachment of gene sequences, exosomes, or protein payloads—opening a path to both direct-to-consumer therapeutics and high-value pharmaceutical applications.
Disrupting humanity through restoration, not evolution.
Arcane has developed a programmable therapeutic platform based on human elastin-like polypeptides (ELPs). These synthetic proteins act as intelligent delivery vehicles capable of targeting specific tissues, responding to biological cues, and triggering regenerative cascades across a broad spectrum of disease states. Our ELP constructs allow for the attachment of gene sequences, exosomes, or protein payloads—opening a path to both direct-to-consumer therapeutics and high-value pharmaceutical applications.
Arcane’s core breakthrough centers on Elastin-Like Polypeptides (ELPs)—programmable biopolymers that act like microscopic delivery drones, but with biologically native precision. These synthetic proteins mimic the behavior of natural elastin, a flexible and abundant protein in human connective tissue, allowing them to navigate the body’s internal environment with minimal disruption. ELPs can be engineered to respond to specific biological cues—such as temperature, pH, or enzymes—triggering the controlled release of therapeutic agents directly at the site of dysfunction.
What makes this transformative is not just the targeted delivery—it’s the ability of ELPs to restore the body’s own biological instructions. Rather than forcing change through brute pharmaceutical force, ELPs act more like cellular reset buttons, realigning dysfunctional tissue behavior and reactivating innate healing pathways. This enables regeneration at a foundational level, promoting repair across skin, nerve, muscle, and metabolic systems.
Crucially, this is achieved without the need for injections, viral vectors, or complex cold-chain logistics. ELPs are non-immunogenic, biodegradable, and scalable, opening the door to a new class of accessible, non-invasive biologic therapies. This foundational platform positions Arcane to address a vast range of chronic and degenerative conditions—not by treating symptoms, but by reprogramming cellular behavior itself.
The ELP Platform
Reactivating the body’s original biological code, restoring cellular behavior to its optimal, uncorrupted state
Arcane’s platform reactivates the body’s original biological code, restoring cellular behavior to its optimal, uncorrupted state. This isn’t about enhancement—it’s about remembering how to heal.
Arcane’s core breakthrough centers on Elastin-Like Polypeptides (ELPs)—programmable biopolymers that act like microscopic delivery drones, but with biologically native precision. These synthetic proteins mimic the behavior of natural elastin, a flexible and abundant protein in human connective tissue, allowing them to navigate the body’s internal environment with minimal disruption. ELPs can be engineered to respond to specific biological cues—such as temperature, pH, or enzymes—triggering the controlled release of therapeutic agents directly at the site of dysfunction.
What makes this transformative is not just the targeted delivery—it’s the ability of ELPs to restore the body’s own biological instructions. Rather than forcing change through brute pharmaceutical force, ELPs act more like cellular reset buttons, realigning dysfunctional tissue behavior and reactivating innate healing pathways. This enables regeneration at a foundational level, promoting repair across skin, nerve, muscle, and metabolic systems.
Crucially, this is achieved without the need for injections, viral vectors, or complex cold-chain logistics. ELPs are non-immunogenic, biodegradable, and scalable, opening the door to a new class of accessible, non-invasive biologic therapies. This foundational platform positions Arcane to address a vast range of chronic and degenerative conditions—not by treating symptoms, but by reprogramming cellular behavior itself.
The ELP Platform
Reactivating the body’s original biological code, restoring cellular behavior to its optimal, uncorrupted state
Arcane’s platform reactivates the body’s original biological code, restoring cellular behavior to its optimal, uncorrupted state. This isn’t about enhancement—it’s about remembering how to heal.
Arcane’s core breakthrough centers on Elastin-Like Polypeptides (ELPs)—programmable biopolymers that act like microscopic delivery drones, but with biologically native precision. These synthetic proteins mimic the behavior of natural elastin, a flexible and abundant protein in human connective tissue, allowing them to navigate the body’s internal environment with minimal disruption. ELPs can be engineered to respond to specific biological cues—such as temperature, pH, or enzymes—triggering the controlled release of therapeutic agents directly at the site of dysfunction.
What makes this transformative is not just the targeted delivery—it’s the ability of ELPs to restore the body’s own biological instructions. Rather than forcing change through brute pharmaceutical force, ELPs act more like cellular reset buttons, realigning dysfunctional tissue behavior and reactivating innate healing pathways. This enables regeneration at a foundational level, promoting repair across skin, nerve, muscle, and metabolic systems.
Crucially, this is achieved without the need for injections, viral vectors, or complex cold-chain logistics. ELPs are non-immunogenic, biodegradable, and scalable, opening the door to a new class of accessible, non-invasive biologic therapies. This foundational platform positions Arcane to address a vast range of chronic and degenerative conditions—not by treating symptoms, but by reprogramming cellular behavior itself.
Arcane’s core breakthrough centers on Elastin-Like Polypeptides (ELPs)—programmable biopolymers that act like microscopic delivery drones, but with biologically native precision. These synthetic proteins mimic the behavior of natural elastin, a flexible and abundant protein in human connective tissue, allowing them to navigate the body’s internal environment with minimal disruption. ELPs can be engineered to respond to specific biological cues—such as temperature, pH, or enzymes—triggering the controlled release of therapeutic agents directly at the site of dysfunction.
What makes this transformative is not just the targeted delivery—it’s the ability of ELPs to restore the body’s own biological instructions. Rather than forcing change through brute pharmaceutical force, ELPs act more like cellular reset buttons, realigning dysfunctional tissue behavior and reactivating innate healing pathways. This enables regeneration at a foundational level, promoting repair across skin, nerve, muscle, and metabolic systems.
Crucially, this is achieved without the need for injections, viral vectors, or complex cold-chain logistics. ELPs are non-immunogenic, biodegradable, and scalable, opening the door to a new class of accessible, non-invasive biologic therapies. This foundational platform positions Arcane to address a vast range of chronic and degenerative conditions—not by treating symptoms, but by reprogramming cellular behavior itself.
A universal platform that goes beyond treating disease, and instead restores and resets the human genome entirely.
Arcane has developed a programmable therapeutic platform based on human elastin-like polypeptides (ELPs). These synthetic proteins act as intelligent delivery vehicles capable of targeting specific tissues, responding to biological cues, and triggering regenerative cascades across a broad spectrum of disease states. Our ELP constructs allow for the attachment of gene sequences, exosomes, or protein payloads—opening a path to both direct-to-consumer therapeutics and high-value pharmaceutical applications.
Consumer-Driven Innovation
Rapid commercialization of ELP-based topicals and ingestibles targeting skin, hair, weight loss, and wound care.
Chronic & Orphan Disease
Development of therapies across neurodegenerative, autoimmune, metabolic, and oncology categories. Enables novel access routes like nasal and topical applications.
Arcane has developed a programmable therapeutic platform based on human elastin-like polypeptides (ELPs). These synthetic proteins act as intelligent delivery vehicles capable of targeting specific tissues, responding to biological cues, and triggering regenerative cascades across a broad spectrum of disease states. Our ELP constructs allow for the attachment of gene sequences, exosomes, or protein payloads—opening a path to both direct-to-consumer therapeutics and high-value pharmaceutical applications.
Arcane’s platform reactivates the body’s original biological code, restoring cellular behavior to its optimal, uncorrupted state. This isn’t about enhancement—it’s about remembering how to heal.
Disrupting humanity itself – not through evolution, but through restoration.
The Breakthrough
A universal platform that goes beyond treating disease, and instead restores and resets the human genome entirely.
Arcane has developed a programmable therapeutic platform based on human elastin-like polypeptides (ELPs). These synthetic proteins act as intelligent delivery vehicles capable of targeting specific tissues, responding to biological cues, and triggering regenerative cascades across a broad spectrum of disease states. Our ELP constructs allow for the attachment of gene sequences, exosomes, or protein payloads—opening a path to both direct-to-consumer therapeutics and high-value pharmaceutical applications.
Arcane's novel approach enables therapies to reach more people, in less time, with greater precision.
Ease of Use & Accessibility
Arcane eliminates the complexity of traditional biologics—no injections, infusions, viral vectors, or cold-chain logistics. Our therapies are delivered topically, intranasally, or orally, requiring no medical personnel or equipment. This not only improves patient comfort and compliance but also expands access to advanced care across underserved and remote areas—reducing systemic burden and accelerating real-world impact.
Rapid, Low-Cost Scalability
Our proprietary bio-production system enables rapid, scalable manufacturing of clinical-grade biologics in weeks—not months—at a fraction of traditional costs. Using food-grade organisms as living bio-factories, we avoid complex infrastructure and regulatory slowdowns. Many formulations qualify under GRAS or food additive pathways, allowing swift deployment in both developed and underserved markets.
Dual-Track Strategy
Arcane’s dual-track model generates immediate revenue through consumer wellness products while building a pipeline of transformative therapeutics. In parallel, we’re developing therapies for orphan and niche diseases—strategically positioned for early exits or licensing. This approach drives cash flow and credibility, while preserving long-term upside as we rewrite the biological code for healing and regeneration.
Dismantling traditional pharma paradigms, enabling treatments to go from lab to market at unprecedented speed.
Therapeutics that collectively exceed $1 trillion in global opportunity
Regenerative Skincare
$809 million by 2032
Weight-Management
$299 billion by 2030
Hair Restoration
$49 billion by 2034
Neurological & Chronic Disease
$700+ billion (varied)
Arcane's flexible delivery methods, rapid scalability, and dual-track commercialization strategy enable us to move faster and more efficiently than legacy players.
The novel ELP platform unlocks scalable, non-invasive delivery of therapeutic payloads—from consumer skincare to gene-sequence-driven immunotherapies. That flexibility isn’t just scientific—it’s commercial.
Arcane’s development pipeline is intentionally designed for speed, scalability, and strategic impact. By leveraging our modular ELP platform, we can rapidly customize and deploy targeted therapeutics across a diverse range of conditions—from cosmetic and regenerative applications to autoimmune, metabolic, and neurodegenerative diseases.
The timeline below outlines the projected rollout of both direct-to-consumer products and clinical-grade therapies, with some innovations already in market and others approaching key milestones.
Arcane's novel approach enables therapies to reach more people, in less time, with greater precision.
Ease of Use & Accessibility
Arcane’s innovative therapeutic approach fundamentally transforms patient experience by eliminating the complexities and discomfort typically associated with biologic treatments. By removing the need for injections, invasive infusions, viral vector deliveries, and cumbersome cold-chain logistics, our products significantly enhance patient compliance, comfort, and accessibility. Our formulations—delivered through simple topical, intranasal, or oral routes—can be effortlessly administered without specialized medical personnel or equipment, effectively democratizing access to cutting-edge therapies. This streamlined method not only broadens patient reach, especially in underserved or remote areas, but also substantially reduces healthcare system burdens, creating a more equitable and efficient path toward widespread adoption and impactful outcomes.
Rapid, Low-Cost Scalability
Our proprietary bio-production system radically accelerates and simplifies the manufacturing of complex biologics. By using genetically modified, food-grade organisms as living bio-factories, we can produce clinical-grade materials at scale within weeks—not months or years—at a fraction of the traditional cost. Many of these formulations qualify under GRAS (Generally Recognized as Safe) or food additive frameworks, enabling us to bypass traditional regulatory bottlenecks. This not only unlocks speed-to-market advantages but also allows us to serve emerging markets and deploy therapeutics in crisis zones or underserved areas with minimal infrastructure.
Dual-Track Strategy
We are executing a high-leverage dual-track model: immediate revenue generation through consumer health and wellness products, paired with a longer-term pipeline of transformative pharmaceutical breakthroughs. This strategy allows us to build brand trust, cash flow, and scientific credibility in parallel. In tandem, we’re rapidly developing highly-targeted therapeutics for orphan and niche diseases—positioned for early exits or licensing opportunities. This approach provides significant non-dilutive capital while preserving long-term upside and keeping us focused on our core mission: rewriting the biological code for human healing and regeneration.
The addressable market is humanity itself.
Arcane is disrupting markets that collectively exceed $1 trillion in global opportunity
Category | Market Size (USD) |
|---|---|
Regenerative Skincare | $809 million by 2032 |
Weight-Management Therapeutics | $299 billion by 2030 |
Hair Restoration | $49 billion by 2034 |
Neurological & Chronic Disease | $700+ billion (varied) |
Our ELP platform unlocks scalable, non-invasive delivery of therapeutic payloads—from consumer skincare to gene-sequence-driven immunotherapies. That flexibility isn’t just scientific—it’s commercial.
Arcane’s development pipeline is intentionally designed for speed, scalability, and strategic impact. By leveraging our modular ELP platform, we can rapidly customize and deploy targeted therapeutics across a diverse range of conditions—from cosmetic and regenerative applications to autoimmune, metabolic, and neurodegenerative diseases.
The timeline below outlines the projected rollout of both direct-to-consumer products and clinical-grade therapies, with some innovations already in market and others approaching key milestones.
Unlocking addressable markets that collectively exceed $1 trillion in global opportunity
Therapeutics that collectively exceed $1 trillion in global opportunity
Arcane's flexible delivery methods, rapid scalability, and dual-track commercialization strategy enable us to move faster and more efficiently than legacy players.
The novel ELP platform unlocks scalable, non-invasive delivery of therapeutic payloads—from consumer skincare to gene-sequence-driven immunotherapies. That flexibility isn’t just scientific—it’s commercial.
Arcane’s development pipeline is intentionally designed for speed, scalability, and strategic impact. By leveraging our modular ELP platform, we can rapidly customize and deploy targeted therapeutics across a diverse range of conditions—from cosmetic and regenerative applications to autoimmune, metabolic, and neurodegenerative diseases.
The timeline below outlines the projected rollout of both direct-to-consumer products and clinical-grade therapies, with some innovations already in market and others approaching key milestones.
Regenerative Skincare
$809 million by 2032
Weight-Management
$299 billion by 2030
Hair Restoration
$49 billion by 2034
Neurological & Chronic Disease
$700+ billion (varied)
The addressable market is humanity itself.
Therapeutics that collectively exceed $1 trillion in global opportunity
Regenerative Skincare
$809 million by 2032
Weight-Management
$299 billion by 2030
Hair Restoration
$49 billion by 2034
Neurological & Chronic Disease
$700+ billion (varied)
Arcane's flexible delivery methods, rapid scalability, and dual-track commercialization strategy enable us to move faster and more efficiently than legacy players
The novel ELP platform unlocks scalable, non-invasive delivery of therapeutic payloads—from consumer skincare to gene-sequence-driven immunotherapies. That flexibility isn’t just scientific—it’s commercial.
Arcane’s development pipeline is intentionally designed for speed, scalability, and strategic impact. By leveraging our modular ELP platform, we can rapidly customize and deploy targeted therapeutics across a diverse range of conditions—from cosmetic and regenerative applications to autoimmune, metabolic, and neurodegenerative diseases.
The timeline below outlines the projected rollout of both direct-to-consumer products and clinical-grade therapies, with some innovations already in market and others approaching key milestones.
Category | Market Size (USD) | Notes |
|---|---|---|
Regenerative Skincare | $809 million by 2032 | Executed soft entry, with immediate revenue opportunity. |
Weight-Management Therapeutics | $299 billion by 2030 | Targeting this with non-injection-based solutions. |
Hair Restoration | $49 billion by 2034 | Fast-growing space; topical therapies give strong advantage. |
Neurological & Chronic Disease | $700+ billion (varied) | Includes neurodegenerative, autoimmune, metabolic, oncology sectors. |
Orphan & Chronic Disease
Development of therapies for autoimmune, degenerative, and rare diseases—strategically positioned for pharmaceutical partnerships.
Therapeutics Pipeline
These timelines represent estimates and are contingent on securing the capital necessary to sustain accelerated development. Our dual-track strategy allows us to generate near-term revenue while simultaneously advancing high-value pharmaceutical assets—accelerating delivery without compromising scientific rigor.
Consumer Innovations
Skincare
Arcane’s initial skincare line uses our original technology to treat aging, acne, and wounds with strong efficacy. A next-gen formulation using our ELP platform is in development, designed to eliminate visible signs of aging—regardless of age—through deep regenerative stimulation.
EST Q3 2025
Acne Serum
Exceeds all expectations in both acne clearance and scar reversal. New formula utilizes carbon quantum dots to improve the delivery of adapalene for enhanced penetration and lasting results.
EST Q3 2025
Wound Serum
An ELP-silk hybrid that self-assembles into nanoparticle sheets at body temperature, delivering healing proteins directly to the wound site. Clinically observed to fully close non-healing diabetic wounds within 30 days and accelerate recovery in burn and lesion cases.
EST Q3 2025
Hair Regeneration
Topical formula using our ELP delivery platform to reprogram miniaturized hair follicles and restore melanocyte stem cells—returning both density and natural hair color.
EST Q4 2025
Weight Loss Therapeutic
A non-injection-based alternative to GLP-1 drugs that reduces fat while preserving lean mass. Demonstrated reversal effects on Alzheimer’s, fatty liver, CKD, and heart disease—all through targeted disruption of aging pathways.
EST Q1 2026
Weight Loss Therapeutic
A non-injection-based alternative to GLP-1 drugs that reduces fat while preserving lean mass. Demonstrated reversal effects on Alzheimer’s, fatty liver, CKD, and heart disease—all through targeted disruption of aging pathways.
EST Q3 2025
Chronic & Orphan Disease
Cancer Immunotherapy (Topical T-cell Reprogramming)
A radical new approach combining three transcription proteins, our ELP platform, and the MR-1 cancer biomarker to reprogram cancer cells into tumor-targeting T-cells. Additional topical probiotic formulation trains naïve T-cells via skin biome modulation.
EST Q1 2026
OSK–ELP Construct
A non-viral gene therapy method that enables safe cellular reprogramming to a pluripotent state—supporting both in-clinic therapies and the generation of HILO cells for Type 1 Diabetes.
EST Q1 2026
Periodontal Disease
Two IL-10-based regenerative therapeutics: one using exosomes, the other a cost-effective ELP construct in thermally responsive hydrogel.
EST Q3 2025
Advanced Wound Care (Clinical)
Silk-derived ELPs that form protein-rich ECM sheets upon contact with the body. Designed to heal wounds with impaired blood or nerve supply.
EST Q3 2025
Epidermolysis Bullosa (EB)
Three therapeutics in development:
Topical ELP–COL7A1 gene therapy
TIMP-1 wound spray to reduce healing time by 50%
Immune-regulating therapy to correct MMP–TIMP imbalance underlying collagen breakdown
EST Q1 2026
Advanced Wound Care (Clinical)
Two therapeutics in development:
-
IL-10 exosomes delivered via inhalation, regenerating spinal cord myelin (ACS Nano Biotech study published)
-
ELP–MOG–PGAL nanoconstruct that re-trains the immune system by selectively erasing autoreactive memory T-cells
EST Q4 2025
Type 1 Diabetes (T1D)
Combines autoimmune suppression via ELP-autoantibody constructs with patient-specific islet transplants derived from skin biopsies and reprogrammed into HILO cells using OSK–ELP. Designed for permanent restoration of insulin independence without viral vectors.
EST Q2 2026
Weight Loss Therapeutic
A non-injection-based alternative to GLP-1 drugs that reduces fat while preserving lean mass. Demonstrated reversal effects on Alzheimer’s, fatty liver, CKD, and heart disease—all through targeted disruption of aging pathways.
EST Q3 2025
Skincare
Q3 2025
Arcane’s initial skincare line uses our original technology to treat aging, acne, and wounds with strong efficacy. A next-gen formulation using our ELP platform is in development, designed to eliminate visible signs of aging—regardless of age—through deep regenerative stimulation.
Weight Loss Therapeutic
Q3 2025
A non-injection-based alternative to GLP-1 drugs that reduces fat while preserving lean mass. Demonstrated reversal effects on Alzheimer’s, fatty liver, CKD, and heart disease—all through targeted disruption of aging pathways.
Acne Serum
Q4 2025
Our acne serum results have been beyond any expectations and have even removed the scarring associated with chronic acne. We have the ability to make carbon quantum dots to attach adapalene to for effective penetration.
Hair Regeneration
Q4 2025
Topical formula using our ELP delivery platform to reprogram miniaturized hair follicles and restore melanocyte stem cells—returning both density and natural hair color.
Chronic & Orphan Disease
Oncology
Q1 2026
We have developed a way using 3 transcription proteins, our ELP construct and the cancer biomarker MR-1 to reprogram cancer cells into T-cells that present the antigen for the cancer and will continue to attack that tumor as well as circulate to find metastasis of similar tumors. Off target effects will produce naïve T-cells that we can educate with our topical technology. We transfect S. Epidermidis with MR-1 and make into a probiotic face cream. Colonies of naïve T-cells aggregate under these colonies of staph epidermidis (the most ubiquitous bacteria in your skin biome) and our topical educates these T-cells. This gives you a T-cell therapy against 85% of cancers.
OSK-ELP Construct
Q1 2026
This novel technology gives you the ability to reprogram cells back to their pluripotent state without the use of viral vectors. This is highly sought after because it gives you the ability to use stem therapies in clinical trials without viral vectors being involved. We are also using this technology ourselves both in our direct-to-consumer products and to make off the shelf HILO cells for islet cell transplants for Type 1 Diabetes.
Periodontal Disease
Q1 2026
We have two therapeutics that reverse periodontal disease. The first is our exosome technology which are IL-10 exosomes in a thermally responsive biomaterial. The second one is an ELP IL-10 construct in the same hydrogel that should provide the same results at a significantly reduced cost. We know this works because we have 20 years of regenerative periodontal therapies experience.
Wound Care
Q1 2026
We have developed a slight variation on our ELP construct which allows us to get silk proteins that self-assemble into nano particles at body temperature that then form into sheets covering the wound, to this we attach four proteins that are necessary for wound healing. These self-assemble into an extracellular matrix sheet that contains all the proteins necessary for wounds to heal even in the absence of good nerve and blood supply.
Epidermolysis Bullosa
Q1 2026
We have developed three therapeutics for this orphan disease based on an interest by the EB Research Foundation. The first one involves a topical gene therapy which replaces the defective genes (ELP – COL7A1 construct). The second is a topical wound care spray that contains TIMP-1 and reduces the time of wound healing by half. The third one corrects the autoimmune imbalance set up by the collagen fragments (this is an MMP-TIMP imbalance that causes the collagen to break down faster than it is produced. This is the main cause of the symptoms that nobody is looking at.
Multiple Sclerosis
Q1 2026
We have two therapies which have been shown to reverse MS. One is a treatment, and one reverses the disease. The first one is an IL-10 exosome in an inhalable delivery vehicle. We have a peer reviewed paper in ACS Nano Biotechnology showing that this systematically regenerates the myelin sheath of the spinal cord and restores mobility. This doesn’t however address the autoimmune component of the disease. Our second therapeutic utilizes our autoimmune platform which attaches MOG protein to our ELP construct. We attach PGAL to the other end. This forms a nano particle at body temperature with the MOG protein at the center and PGAL on the outside. The PGAL shuttles the construct to the liver where it is broken down recognized as self and the autoimmune response is trained out of the patient by selectively removing the memory of the T-cells. This approach works for any autoimmune disease as long as you know the offending protein.
Type 1 Diabetes
3 mo.
Our world-renowned scientists have been working in T1D for the last 30 years. Jonathan Lakey, PhD, was instrumental in the very first islet cell transplant in the year 2000 and was published in The New England Journal of Medicine. Twenty-five years later we now have a way to train the autoimmune disease out of the patient and restore them to a normal insulin response. This therapy utilizes our autoimmune platform by attaching the four autoantibodies to the ELP and to PGAL which shuttles the construct to the liver and trains the autoimmune response out of the patient by removing the memory of the T-cells. We think this will take 4-6 months of treatment which gives time to take a skin biopsy from the patient and convert those into patient specific HILO cells for an islet cell transplant once the autoimmune part of the disease is addressed. We can make these HILO cells using our ELP-OSK construct which completely avoids viral vectors.
Arcane’s platform unlocks
addressable markets that
collectively exceed $1
trillion in global
opportunity
Arcane is strategically positioned at the intersection of multiple high-growth markets—each representing urgent, unmet needs across regenerative medicine, chronic disease, and aesthetic health. Our platform technology allows us to pursue several billion-dollar categories in parallel, with the ability to rapidly create new formulations and access underserved segments without the regulatory drag typical of traditional pharma.
From skin regeneration and post-surgical healing, to weight management, hair restoration, and neurodegenerative disease, Arcane’s platform unlocks addressable markets that collectively exceed $1 trillion in global opportunity—while our flexible delivery methods, rapid scalability, and dual-track commercialization strategy enable us to move faster and more efficiently than legacy players.